NDC 70436-033

daptomycin

Daptomycin

daptomycin is a Intravenous Injection, Powder, Lyophilized, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Slate Run Pharmaceuticals, Llc. The primary component is Daptomycin.

Product ID70436-033_e6b9cc81-2724-1ecb-e053-2995a90a13c1
NDC70436-033
Product TypeHuman Prescription Drug
Proprietary Namedaptomycin
Generic NameDaptomycin
Dosage FormInjection, Powder, Lyophilized, For Suspension
Route of AdministrationINTRAVENOUS
Marketing Start Date2022-10-01
Marketing CategoryANDA /
Application NumberANDA215890
Labeler NameSlate Run Pharmaceuticals, LLC
Substance NameDAPTOMYCIN
Active Ingredient Strength500 mg/20mL
Pharm ClassesLipopeptide Antibacterial [EPC], Lipopeptides [CS]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70436-033-80

20 mL in 1 VIAL, SINGLE-DOSE (70436-033-80)
Marketing Start Date2022-10-01
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "daptomycin" or generic name "Daptomycin"

NDCBrand NameGeneric Name
0143-9378DaptomycinDaptomycin
0409-0106DaptomycinDAPTOMYCIN
0409-0120DaptomycinDAPTOMYCIN
0409-0122DaptomycinDAPTOMYCIN
0409-2757DaptomycinDAPTOMYCIN
0409-5933DaptomycinDaptomycin
0703-0125DaptomycinDaptomycin
0781-3295daptomycindaptomycin
16714-892DaptomycinDaptomycin
16729-434DaptomycinDaptomycin
16729-435DAPTOMYCINDaptomycin
25021-174daptomycindaptomycin
25021-179DaptomycinDaptomycin
70594-034DaptomycinDaptomycin
70594-053DaptomycinDaptomycin
63323-871DaptomycinDaptomycin
63323-371DaptomycinDaptomycin
67457-813daptomycindaptomycin
43598-413DaptomycinDaptomycin
68001-376DaptomycinDaptomycin
63323-585DaptomycinDaptomycin
71839-107daptomycindaptomycin
57884-3151DaptomycinDaptomycin
69097-807DaptomycinDaptomycin
72572-102DaptomycinDaptomycin
72572-100DaptomycinDaptomycin
45932-0039DaptomycinDaptomycin
71288-018DAPTOMYCINDAPTOMYCIN
76233-091DaptomycinDaptomycin
31722-102DaptomycinDaptomycin

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.